Fluoxetine response: endpoint vs pattern analysis.

Abstract	A 6-week double-blind trial of fluoxetine treatment of unipolar major depressive disorder in 49 patients was evaluated in terms of improvement in the Hamilton Depression Rating Scale (HDRS) and Clinical Global Improvement (CGI) scores. A relationship was found between change in HDRS (absolute and percentage decrease from baseline) and final CGI ratings. However, because of a few placebo-responders, endpoint analysis with both the HDRS and CGI showed no differences between active drug and placebo. Pattern analysis of persistent response did successively separate active drug from placebo (less than 0.05).
Authors	R R Fieve, P J Goodnick, E Peselow, A Schlegel
Journal	International clinical psychopharmacology (Int Clin Psychopharmacol) Vol. 1 Issue 4 Pg. 320-3 (Oct 1986) ISSN: 0268-1315 [Print] England
PMID	3549877 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article, Randomized Controlled Trial)
Chemical References	Propylamines Fluoxetine
Topics	Adolescent Adult Aged Clinical Trials as Topic Depressive Disorder (drug therapy) Double-Blind Method Female Fluoxetine (therapeutic use) Humans Male Middle Aged Propylamines (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!